AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.14
0.10 (9.62%)
▲
5d:
+6.54%
30d:
+10.68%
90d:
-17.99%
HOLD
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: AKBA is 7.5% above its trading range ($1.06). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: AKBA is 7.5% above its trading range ($1.06). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.14, which is considered extended relative to its 30-day fair value range of $0.93 to $1.06. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.0) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a strong downtrend. The price is approaching resistance at $1.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.6% recently.
Market Sentiment: AKBA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.20 (+268.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AKBA is in a strong downtrend. The price is approaching resistance at $1.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.6% recently.
Market Sentiment: AKBA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.20 (+268.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.93 -
$1.06
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.6%)
- BULLISH: Trading 268.4% below Wall St target ($4.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Extended 7.5% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$0.93 -
$1.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.88
Resistance Level
$1.14
Current Trend
Strong Downtrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.00
Wall Street Target
$4.20
(+268.4%)
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
PE vs Historical
-6.0 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: June 29, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Richard C Malabre
SELL
49524 shares
2026-02-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 54 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
